Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers - Trial NCT06339788
Access comprehensive clinical trial information for NCT06339788 through Pure Global AI's free database. This Phase 1 trial is sponsored by Handok Inc. and is currently Not yet recruiting. The study focuses on Healthy Volunteers. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Handok Inc.
Timeline & Enrollment
Phase 1
Apr 01, 2024
Nov 01, 2024
Primary Outcome
Area under the plasma concentration versus time curve (AUCt) of Teneligliptin and Empagliflozin,Peak Plasma Concentration (Cmax) of Teneligliptin and Empagliflozin
Summary
The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and
 coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06339788
Non-Device Trial